New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
09:13 EDTCRTO, SHPG, AOL, GMED, FUEL, CYTX, CTSH, AMPH, MNKD, ENPH, FSLR, WAG, NUS, GRPN, FOXA, TMUS, TWX, SOn The Fly: Pre-market Movers
HIGHER: Fox class A shares (FOXA), up 5.9% after withdrawing proposal to acquire Time Warner (TWX), announcing $6B share repurchase program, reporting quarterly results... MannKind (MNKD), up 1.6% after entering a supply agreement with Amphastar Pharmaceuticals (AMPH)... Criteo (CRTO), up 11.5% after upgraded at Goldman following its better than expected Q2 earnings report. LOWER: Time Warner (TWX), down 13% after earnings, maintaining guidance, bid dropped by Fox... Sprint (S), down 16.5% after naming Marcelo Claure as president and CEO, reportedly dropping pursuit of T-Mobile (TMUS). T-Mobile shares also down 8.5%... Groupon (GRPN), down 18%, downgraded at Wunderlich after the company reported lower than expected Q3 results... Walgreen (WAG), down 15.7% after exercises option to acquire remaining 55% of Alliance Boots, says it will not pursue inversion as part of deal... Shire (SHPG), down 6% after Walgreen announced it would stay located in Chicago and Bloomberg last night reported that the Treasury Department is exploring ways to bypass Congress in an attempt to curb corporate inversions... Cytori Therapeutics (CYTX), down 33% after announcing that it has placed enrollment in the ATHENA and ATHENA II trials on clinical hold. UP AFTER EARNINGS: Enphase Energy (ENPH), up 20%... AOL (AOL), up 5%. DOWN AFTER EARNINGS: Nu Skin (NUS), down 8.5%... Rocket Fuel (FUEL), down 27%... Cognizant (CTSH), down 13%... First Solar (FSLR), down 2.5%... Globus Medical (GMED), down 17%.
News For TWX;FOXA;S;TMUS;WAG;GRPN;NUS;FSLR;ENPH;MNKD;AMPH;CYTX;FUEL;CTSH;AOL;CRTO;GMED;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
January 26, 2016
08:13 EDTFSLRFirst Solar initiated with a Buy at Roth Capital
Subscribe for More Information
08:12 EDTCRTOCriteo initiated with an Equal Weight at Morgan Stanley
Subscribe for More Information
07:56 EDTSSprint up 16% after raising adjusted EBITDA view
Subscribe for More Information
07:53 EDTSRBC Capital to hold a field trip
Brazil Telecoms Trip travels throughout Sao Paulo, Brazil visiting with various companies on January 26-27.
07:45 EDTSSprint establishing network-related financing entity in partnership with SoftBank
Subscribe for More Information
07:43 EDTSSprint reports Q3 postpaid phone net additions of 366,000
Subscribe for More Information
07:40 EDTSSprint sees FY16 Adjusted EBITDA rising to $9.5B-$10B
Subscribe for More Information
07:39 EDTSSprint raises FY15 adjusted EBITDA view to $7.7B--$8B from $6.8B-$7.1B
Subscribe for More Information
07:33 EDTSSprint reports Q3 adjusted EBITDA of $1.9B
Sprint reported net operating revenue of $8.1B, operating loss of $197M, and Adjusted EBITDA of $1.9B.
07:32 EDTSSprint reports Q3 EPS (21c), consensus (25c)
Subscribe for More Information
06:37 EDTSCertain Sprint users get $5 discount for watching mobile ads, WSJ says
Subscribe for More Information
January 25, 2016
14:29 EDTSNotable companies reporting before tomorrow's open
Subscribe for More Information
14:21 EDTSSprint confirms over 2,500 jobs eliminated in latest cuts, KC Star reports
Subscribe for More Information
09:04 EDTS, TMUSSprint doubles number of LTE Plus markets
Subscribe for More Information
07:32 EDTSTMC to hold a conference
Subscribe for More Information
07:02 EDTSHPGShire resubmits NDA for lifitegrast to FDA
Subscribe for More Information
07:02 EDTCYTXCytori Therapeutics says Phase 3 STAR trial treats 20th patient
Cytori Therapeutics announced that its U.S. FDA approved Phase 3 STAR trial has enrolled and treated its 20th patient -- 25% of target enrollment. In addition, as per the trial protocol, an independent data monitoring committee has reviewed safety data from the initial 10 patients and recommended that the study continue as planned. The 20 procedures, including the fat harvest from small volume liposuction and the finger injections have all been completed successfully and well tolerated. STAR is a randomized, placebo-controlled, double-blind, parallel group phase III FDA approved pivotal study investigating the efficacy and safety of Cytori Cell Therapy (ECCS-50) injected subcutaneously into the fingers of patients with impaired hand function from scleroderma. A total of 80 patients will be randomized with 40 receiving Cytori Cell Therapy and 40 receiving placebo. The double-blind period extends to 48 weeks. After all patients have completed 48 weeks follow-up, the placebo patients will be offered active treatment should they desire treatment and continue to qualify. The trial began enrollment in August 2015 with enrollment expected to be completed by mid-2016. The STAR trial follows the twelve patient SCLERADEC-I pilot trial in which one year post-treatment results were published in the August 2015 edition of the journal Rheumatology. The data indicated that a single administration of ECCS-50 was safe and that treated patients exhibited significant improvements in hand symptoms, function and Raynaud's Phenomena through one-year post-treatment.
05:19 EDTSStocks with implied volatility movement; SWN SCTY
Subscribe for More Information
January 24, 2016
18:28 EDTTWXAT&T potentially circling Time Warner, New York Post says
Subscribe for More Information
17:55 EDTFOXA'The Revenant' tops box office as 'Ride Along 2' sags
"The Revenant" clawed past "Ride Along 2" as this weekend's snow storm left several box office newcomers grasping for ticket sales. WEEKEND LEADER: Fox's (FOX, FOXA) "The Revenant" grossed $16M domestically for the weekend of January 24. The Leonardo DiCaprio-led survival Western was expected to take $19M-$21.6M, though results may have been dampened by the East Coast winter storm. BOX OFFICE RUNNERS-UP: Disney's (DIS) "Star Wars: The Force Awakens" earned $14.3M and now stands at $1.94B globally. Comcast (CMCSA, CMCSK) subsidiary Universal's "Ride Along 2" dipped to $13M against expectations for $18M-$18.7M, with critics and audiences generally lukewarm on the film despite its $34M open last weekend. Rounding out the weekend's top five were Lionsgate's (LGF) "Dirty Grandpa" and STX Entertainment's "The Boy," with the two newcomers debuting at a respective $11.5M and $11.3M.
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use